Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy' during the lockdown period as the majority of their revenue comes from clients whose laboratories are regarded as "essential businesses" with many working on COVID-19 related vaccines and therapies.
Instem PLC's Phil Reason says they've been really busy during lockdown and welcomes new Korea deal
Quick facts: Instem PLC
Price: 515 GBX
Market Cap: £105.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE